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Smoking Status and Long-Term Survival
After First Acute Myocardial Infarction
A Population-Based Cohort Study
Yariv Gerber, PHD,* Laura J. Rosen, PHD,† Uri Goldbourt, PHD,* Yael Benyamini, PHD,§
Yaacov Drory, MD,‡ for the Israel Study Group on First Acute Myocardial Infarction
Tel Aviv, Israel
Objectives We compared long-term survival after acute myocardial infarction (AMI) of never-smokers, pre-AMI quitters, post-
AMI quitters, and persistent smokers and assessed whether cigarette reduction among persistent smokers is
associated with lower mortality.
Background Quitting smoking has been shown to improve outcome after AMI. However, longitudinal cohort data with re-
peated assessments of smoking and information on multiple confounders are lacking. Moreover, little is known
about the importance, if any, of reductions in the amount smoked.
Methods Consecutive patients 65 years of age, discharged from 8 hospitals in central Israel after first AMI in 1992 to
1993, were followed through 2005. Extensive data, including self-reported smoking habits, were obtained at
baseline and 4 times during follow-up. Cox proportional hazards regressions were used to assess the hazard ra-
tios (HRs) for death associated with smoking categories modeled as time-dependent variables.
Results At baseline, smokers were younger, more likely to be male, and had a lower prevalence of hypertension and dia-
betes than nonsmokers. Over a median follow-up of 13.2 years, 427 deaths occurred in 1,521 patients. The
multivariable-adjusted HRs for mortality were 0.57 (95% confidence interval [CI]: 0.43 to 0.76) for never-
smokers, 0.50 (95% CI: 0.36 to 0.68) for pre-AMI quitters, and 0.63 (95% CI: 0.48 to 0.82) for post-AMI quitters,
compared with persistent smokers. Among persistent smokers, upon multivariable adjustment including pre-AMI
intensity, each reduction of 5 cigarettes smoked daily after AMI was associated with an 18% decline in mortality
risk (p  0.001).
Conclusions Smoking cessation either before or after AMI is associated with improved survival. Among persistent smokers,
reducing intensity after AMI appears to be beneficial. (J Am Coll Cardiol 2009;54:2382–7) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.020h
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smoking is a well-established risk factor for cardiovascular
isease (CVD) development (1,2) and is included in the
ramingham prediction score (3). Paradoxically, a lower
ase-fatality rate associated with smoking shortly after acute
yocardial infarction (AMI) has been commonly reported
4–6). However, this “smoker’s paradox” is largely attribut-
ble to the younger age and better CVD profile of AMI
mokers compared with nonsmokers. Longer-term prospec-
ive investigations have clearly demonstrated considerable
ortality risk reduction associated with smoking cessation
fter AMI (7,8). However, methodological limitations in-
rom the Departments of *Epidemiology and Preventive Medicine, †Health Promo-
ion, School of Public Health, and ‡Rehabilitation, Sackler Medical School, and the
Bob Shapell School of Social Work, Tel Aviv University, Tel Aviv, Israel. This work
as supported in part by the Israel National Institute for Health Policy and Health
ervices Research.s
Manuscript received August 7, 2009; revised manuscript received September 23,
009, accepted September 30, 2009.erent in the current published data leave uncertainties
bout key issues. Indeed, previous studies were mostly small
n size and limited in follow-up period (up to 10 years), were
ften unable to ascertain whether former smokers quit
efore or after the AMI, and have not adequately controlled
or essential confounding factors (reviewed in [7–9]). In
ddition, there is an ongoing debate whether smoking
eduction improves outcome in the general population, and
onflicting results have been reported (10–12). Moreover,
o this end, no data are available on smoking reduction and
utcome after AMI. Lastly, a few studies have incorporated
egular assessment of smoking status during follow-up. This
s critical, given earlier reports of long-term repeated cycles
f smoking abstinence and relapse after AMI (13), which
ight result in substantial misclassification.
With data from a prospective population-based cohort
tudy of incident AMI patients with repeated assessments of
moking, our goals were: 1) to evaluate long-term survival of
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December 15/22, 2009:2382–7 Smoking and Survival After Myocardial Infarctionever-smokers, pre-AMI quitters, post-AMI quitters, and
ersistent smokers; and 2) to examine whether cigarette
eduction is associated with lower mortality risk.
ethods
tudy design and setting. The Israel Study of First Acute
yocardial Infarction is a longitudinal, prospective investi-
ation of the role of sociodemographic, medical, and psy-
hosocial variables measured in patients hospitalized with
ncident (i.e., first-ever) AMI in long-term clinical out-
omes, psychosocial adjustment, and quality of life (14–16).
etween February 15, 1992, and February 15, 1993, a total
f 1,626 consecutive AMI patients 65 years of age or less
ere admitted to 8 Israeli medical centers. These hospitals
rovide care to the entire population of central Israel. Of
hese patients, 81 (5%) died during hospital stay, leaving
,545 eligible candidates for the study, among whom 1,521
98%) consented to participate and completed the
ollow-up.
The diagnosis of AMI was established by the presence of
t least 2 of the following criteria: 1) characteristic chest
ain lasting at least 20 min; 2) creatine kinase elevation
1.5 times the upper limit of normal or creatine kinase
yocardial band fraction5% when simultaneous reference
reatine kinase levels exceeded the upper limit of normal;
nd 3) electrocardiographic changes compatible with
-wave or non–Q-wave AMI. All diagnoses were verified
y an experienced cardiologist (Dr. Drory). Subjects with
rior infarction were excluded.
Data at study entry and during follow-up were obtained
hrough structured interviews, psychosocial questionnaires,
nd review of the entire medical record. A comprehensive
linical follow-up was performed through December 31,
005. Participants were interviewed 5 times: before dis-
harge (T1) and at 3 to 6 months (T2), 1 to 2 years (T3), 5
ears (T4), and 10 to 13 years (T5) after AMI. All aspects
f the study were approved by the appropriate institutional
eview boards.
moking status assessment. Data on smoking were ob-
ained with structured interviews. Smoking habits including
ntensity (number of cigarettes smoked/day), duration (years
f smoking), and time since cessation (if applicable) were
eported at T1, with the former reassessed at all follow-up
nterviews (T2 to T5). In the initial interview (approxi-
ately 1 week after the index AMI), patients were asked
bout their smoking habits before the event. In the follow-
ng interviews, the questions referred to both present smok-
ng behavior and smoking habits since last interview. Pa-
ients were categorized into never-smokers, pre-AMI
uitters, post-AMI quitters, and persistent smokers. Pre-
MI quitting was defined as abstinence for more than 6
onths before the index AMI (17). Intermittent smoking
etween interviews was classified as smoking (18).
ociodemographic variables. Demographic and socioeco-
omic status (SES) measures were self-reported and in- gluded the following variables:
rigin (classified as Mid-Eastern
s. North American/Israeli),
amily income relative to the na-
ional average (categorized as be-
ow average, average, and above
verage), education (years of
chooling), and employment be-
ore the index AMI (dichoto-
ized as part- or full-time em-
loyment vs. none).
linical variables. Clinical data
ere reviewed and verified by a
enior cardiologist. The entire in-
atient and outpatient medical
ecords and data obtained through
tructured detailed interviews were
sed to ascertain CVD risk factors,
MI characteristics and severity
ndexes, and co-interventions. Measurements recorded at the
ndex hospital stay or at the closest time before or after the
ndex date were considered. Obesity was defined as body mass
ndex 30 kg/m2. Diabetes, hypertension, and dyslipidemia
ere defined clinically. Leisure time physical activity was
elf-reported and dichotomized into active versus nonactive in
he year before the index AMI. Comorbidity was assessed by
he Charlson index (19) and analyzed categorically (no comor-
idity for 0 points, moderate comorbidity for 1 to 2 points, and
evere comorbidity for 3 points or more). The AMI charac-
eristics and severity indexes included infarct type and location,
nd Killip class. Reperfusion therapy and revascularization
ncluded thrombolysis, percutaneous transluminal coronary
ngioplasty (PTCA), and coronary artery bypass grafting
CABG). Early revascularization referred to procedures per-
ormed within 45 days of the index date. Cardiovascular events
ccurring during follow-up (recurrent AMI, unstable angina
ectoris, heart failure, PTCA, and CABG) were also
onsidered.
ortality assessment. Mortality follow-up began at the
ate of the index hospital stay and lasted through December
1, 2005 (median 13.2 years; interquartile range [IQR] 12.0
o 13.5 years). Death was ascertained through various
ources, including data from the Israeli Population Registry,
eath certificates, hospital charts, family physicians, and
amily members.
tatistical analyses. Data are presented as percentage,
ean  SD, or median (IQR). Baseline characteristics
cross smoking categories were compared by the chi-square
est for categorical variables and analysis of variance for
ontinuous variables.
Cox proportional hazards models (20) were constructed
o evaluate the hazard ratios (HRs) and 95% confidence
ntervals (CIs) for death associated with smoking categories
andled as time-dependent covariates. These regressions
odel the effects of subjects transferring from one exposure
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CABG  coronary artery
bypass surgery
CI  confidence interval
CVD  cardiovascular
disease
HR  hazard ratio
IQR  interquartile range
PTCA  percutaneous
transluminal coronary
angioplasty
RR  relative risk
SES  socioeconomic
statusroup to another. Initial adjustment was made for age and
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Smoking and Survival After Myocardial Infarction December 15/22, 2009:2382–7ex. A subsequent model additionally adjusted for SES
easures (origin, education, income, and employment sta-
us), traditional risk factors (hypertension, dyslipidemia,
iabetes, obesity, and physical inactivity), AMI characteris-
ics and severity indexes (Q-wave AMI, anterior AMI,
illip class, and comorbidity score), and co-interventions
thrombolysis and early revascularization procedures).
astly, a fully adjusted model further controlled for CVD
vents occurring during follow-up (recurrent AMI, CABG,
TCA, unstable angina pectoris, and heart failure) modeled
s time-dependent covariates. In a complementary analysis,
andom-effects Cox models were examined (21), accounting
or potential intra-hospital correlation. This analysis yielded
irtually identical results as the fixed-effects models, sug-
esting negligible random medical center effects in these
ata. The proportional hazards assumption was tested with
he Schoenfeld residuals, with no violations detected. There
ere no missing values in the covariates used in the
egression analyses, except for family income (17%) and
re-AMI physical activity (8%), for which indicator vari-
bles representing unknown values were included when
ppropriate. All p values were 2-tailed.
esults
he analysis was based on 1,521 first AMI patients, with a
ean age of 54 8 years at the index date and 19% women.
Baseline Characteristics by Smoking CategoryTable 1 Baseline Characteristics by Smokin
Characteristics Overall Never-Smo
n 1,521 418
Age, yrs 54 8 56 7
Male 81 62
Mid-Eastern origin 32 31
Education, yrs 11.0 4.3 10.8 4
Family income
Above average 25 24
Average 28 23
Below average 47 53
Pre-AMI employment 76 65
Anterior AMI 42 46
Q-wave AMI 75 69
Killip class 1 21 24
Comorbidity index, points
0 61 60
1–2 35 35
3 4 6
Hypertension 38 50
Diabetes 25 30
Dyslipidemia 37 40
Obesity 19 22
Pre-AMI physical activity 26 28
Thrombolysis 41 35
CABG within 45 days 6 7
PTCA within 45 days 17 17Values are mean  SD or % unless otherwise indicated.
AMI  acute myocardial infarction; CABG  coronary artery bypass surgerne-half of the participants (50%) had 12 years of
ducation, 47% rated their family income as below average,
nd 76% were employed before the index AMI. Baseline
moking categories included never-smokers (n  418,
7.5%), former smokers (n  305, 20.0%), and smokers
n  798, 52.5%; men, 56.4%, women, 35.6%). For former
mokers, the median abstinence duration at the index AMI
as 10 (IQR 5 to 18) years. Among smokers at AMI, the
verage number of cigarettes smoked/day was 31 16—32
7 men versus 26  13 for women. The baseline charac-
eristics across smoking categories are presented in Table 1.
n average, smokers were younger, more likely to be male,
ad lower prevalence of hypertension and diabetes, and were
ess frequently engaged in leisure-time physical activity than
onsmokers. Former smokers were characterized by a more
avorable SES profile compared with other categories.
Among smokers at the index date, the point abstinence
ates among survivors were 70% at T2, 62% at T3, 55% at
4, and 59% at T5. The respective continuous abstinence
ates were 59% at T3, 44% at T4, and 35% at T5.
ong-term survival by smoking category. Over a total of
7,453 person-years of follow-up, 427 patients died (n 
23 never-smokers, n  70 former smokers, and n  234
urrent smokers according to baseline classification), of which
02 (71%) were cardiac deaths. Overall survival differed sub-
tantially among the smoking categories (Table 2). In a Cox
tegory
Former Smokers Current Smokers p Value
305 798
56 7 52 8 0.001
91 87 0.001
27 35 0.03
12.0 4.2 10.7 4.0 0.001
0.001
34 27
29 35
37 38
82 79 0.001
37 43 0.09
73 78 0.002
20 20 0.13
0.54
62 62
33 35
5 4
44 29 0.001
30 20 0.001
38 34 0.14
17 18 0.12
33 22 0.001
39 45 0.004
9 5 0.02
21 16 0.24g Ca
kers
.7y; PTCA  percutaneous transluminal coronary angioplasty.
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December 15/22, 2009:2382–7 Smoking and Survival After Myocardial Infarctionegression with smoking categories modeled as time-varying
ovariates—after adjustment for SES measures, traditional
isk factors, AMI characteristics and severity indexes, and
ointerventions—the HRs for death were 0.57 (95% CI:
.43 to 0.75) for lifelong nonsmoking, 0.52 (95% CI: 0.37
o 0.71) for pre-AMI quitting, and 0.60 (95% CI: 0.45 to
.79) for post-AMI quitting, compared with persistent
moking (all p  0.001). Further adjustment for CVD
vents occurring during follow-up yielded respective HRs of
.57 (95% CI: 0.43 to 0.76), 0.50 (95% CI: 0.36 to 0.68),
nd 0.63 (95% CI: 0.48 to 0.82) (Fig. 1). In pairwise
omparisons, no significant differences were detected among
ever-smokers, pre-AMI quitters, and post-AMI quitters
all p values  0.20).
Comparably, the estimated effect sizes for being normo-
ensive (HR: 0.74, 95% CI: 0.60 to 0.91) or nondiabetic
HR: 0.67, 95% CI: 0.53 to 0.83) and for undergoing
TCA (HR: 0.58, 95% CI: 0.44 to 0.76) were similar or
maller than that of quitting smoking.
moking reduction and long-term survival. Among per-
istent smokers (n  381; 115 deaths), after multivariable
djustment for baseline characteristics (including SES mea-
ures, traditional risk factors, AMI characteristics and se-
Figure 1 Multivariable-Adjusted HRs
(95% CIs) of Death for Smoking Categories
Adjusted association between smoking categories modeled as time-varying
covariates and long-term mortality after acute myocardial infarction (AMI) (see
final model for the variables controlled for in Table 2). CI  confidence interval;
HR  hazard ratio.
Long-Term Mortality Risk After First AMI AssociWith Smoking Categories Modeled as Time-VaryTable 2 Long-Term Mortality Risk After FirsWith Smoking Categories Modeled
Smoking Categories
Ha
Unadjusted Age- and Sex-
Never-smokers 0.78 (0.61–1.00) 0.54 (0.42–
Pre-AMI quitters 0.57 (0.43–0.77) 0.43 (0.32–
Post-AMI quitters 0.60 (0.46–0.78) 0.55 (0.42–
Persistent smokers 1.00 (reference) 1.00 (refere
*Adjusted for age, sex, origin (Mid-Eastern vs. North American/Israeli)
average), pre-AMI employment, hypertension, dyslipidemia, diabetes,
comorbidity (none, moderate, and severe), thrombolysis, CABG, and
pectoris, and heart failure occurring during follow-up (modeled as tim
CI  confidence interval; other abbreviations as in Table 1.aerity indexes, and co-interventions) and pre-AMI inten-
ity, each reduction of 5 cigarettes smoked/day after the
MI (i.e., average consumption during T2 to T4) was
ssociated with an 11% decline (95% CI: 3% to 19%, p 
.01) in mortality risk. Further adjustment for CVD events
ccurring during follow-up yielded an estimated decline of
8% (95% CI: 9% to 25%, p  0.001).
iscussion
he primary finding of this study is that lifetime nonsmok-
ng and quitting before or after initial AMI confer survival
enefits on post-MI patients. Among survivors of initial
MI, never-smokers had roughly one-half the risk of dying
han those who continued to smoke after AMI. Those
mokers who quit before AMI and those who quit after
MI significantly decreased their risk of dying, as compared
ith persistent smokers (pre-AMI quitters: HR: 0.50; 95%
I: 0.36 to 0.68; post-AMI quitters: HR: 0.63; 95% CI:
.48 to 0.82). Furthermore, reduction of daily cigarettes
mong those who continued to smoke was associated with
igher survival (each reduction of 5 cigarettes smoked/day
fter AMI was associated with an 18% [95% CI: 9% to 25%]
ecline in mortality risk).
At the time of enrollment in 1992 to 1993, 53% of
atients were current smokers (men, 56%; women, 36%),
0% were former smokers, and 27% were never-smokers.
hus, smoking prevalence in this population was consider-
bly higher than the prevalence of smoking in the Israeli
opulation (1992 data: Jewish men, 41%; Jewish women,
9%) (22) and suggests that smokers are overrepresented
mong AMI victims.
Of those smokers who underwent AMI, the point absti-
ence rates throughout the follow-up were 50% to 70%.
urthermore, more than one-third (35%) were continuously
bstinent for at least 10 years. These numbers are consistent
ith previous reports that 28% to 74% of smokers quit after
MI (23,24). Our numbers on successful cessation after
MI suggest a relatively low recidivism rate, which pro-
uces an unusually high long-term success rate for quitting
moking. By comparison, according to current U.S. docu-
ents (25), approximately 44% of smokers attempt to quit
ovariatesI Associated
me-Varying Covariates
atio (95% CI) for Death
ed Multivariable-Adjusted* Multivariable-Adjusted†
0.57 (0.43–0.75) 0.57 (0.43–0.76)
0.52 (0.37–0.71) 0.50 (0.36–0.68)
0.60 (0.45–0.79) 0.63 (0.48–0.82)
1.00 (reference) 1.00 (reference)
tion (years of schooling), income (below average, average, and above
, physical activity, Q-wave AMI, anterior AMI, Killip class (1 vs. 2),
†Further adjusted for recurrent AMI, CABG, PTCA, unstable angina
g covariates).ateding Ct AM
as Ti
zard R
Adjust
0.71)
0.57)
0.72)
nce)
, educa
obesity
PTCA.nnually, but only 4% to 7% succeed.
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Smoking and Survival After Myocardial Infarction December 15/22, 2009:2382–7enefit of quitting: compare strength of association with
hat of other studies. The benefits of quitting smoking
mong individuals in the general population and among
atients with coronary heart disease are well documented.
lthough the exact toxic components of cigarette smoke
nd the potential mechanisms leading to cardiovascular
ysfunction remain to be determined, clinical and experi-
ental studies indicate that smoking promotes lipid oxida-
ion, inflammation, and thrombosis, with oxidative stress
laying a pivotal mechanistic role (26). The landmark study
f British physicians by Doll et al. (2) showed that quitting
hroughout life conferred survival advantages. Those smok-
rs who quit early had larger gains in life expectancy. Those
ho quit by age 30 years avoided most of the added risk,
essation at age 50 years halved the additional hazard, and
ven quitting at age 60 years conferred significant survival
dvantage. Notably, a lower age-standardized mortality rate
as demonstrated in that study in former versus current
mokers for all principal CVD categories (i.e., ischemic
eart disease, cerebrovascular disease, and other vascular
isease). In a systematic review, Critchley and Capewell (8)
ound that cardiac patients who quit smoking reduced their
isks by 36% (relative risk [RR]: 0.64, 95% CI: 0.58 to 0.71),
ith reductions ranging from 7% to 66% (on the basis of
rude RRs). Wilhelmsen (22) found that reductions in
ortality caused by stopping smoking among patients with
oronary disease varied from 38% to 70%. Wilson et al. (7)
eviewed the published data for the effect of cessation on
ortality after infarction and found that the RR reductions
n mortality ranged from 15% to 61%, with a combined RR
stimate of 0.54 (95% CI: 0.46 to 0.62). Thus, our figures of
educed mortality risk of 50% for those who quit pre-AMI
nd 37% reduction in mortality risk for those who quit after
MI are consistent with figures found in shorter-term
nvestigations.
oes reduction help? Although there has been extensive
esearch performed on the benefits of quitting, study of the
enefits accrued from reduction of smoking has received
omewhat less attention. Previous findings showing a mono-
onic dose–response relationship between number of cigarettes
moked and mortality (27) suggest that reduction in the
umber of cigarettes might lead to reduced risk of mortality.
owever, in the few published studies of smoking reduction
nd mortality (10,12), the hypothesized positive effect of
eduction on mortality has not been borne out. No differences
n all-cause mortality between reducers and sustained heavy
mokers were observed in large prospective cohort studies
onducted in Copenhagen (10) and Norway (12). The results
f both of these studies conflict with our data.
There are several possible explanations for differences in the
esults. First, the study populations were different. The Nor-
egian (Tverdal) study was based on a population cohort that
xcluded individuals with previous AMI. The Copenhagen
Godtfredsen) study was based on 3 population cohorts and
ot restricted to post-AMI patients. Therefore, 1 possible
xplanation for the differences in findings is that the benefits of ieduction for post-AMI individuals do not exist in the general,
ealthier population. A second difference concerns definition
f reducers: in both the Tverdal and Godtfredsen studies,
reducers” were defined as individuals who had reduced smok-
ng by at least 50%. Our study, by contrast, used reported
umbers of cigarettes smoked at each time point. If a dose–
esponse relationship exists between amount of reduction and
ortality, our study had greater power to detect an effect than
he 2 previous studies. A third explanation for the differences in
he results is that smoking reduction in the general population
ight be associated with poor health status, with true gains in
ife expectancy due to reduction masked by the higher risk
rofile of reducers. Because our study participants were all
ost-AMI, the underlying risk profile of reducers and non-
educers might have been more similar than the comparative
rofiles of reducers and non-reducers in the general population,
hus allowing a less-biased comparison.
ethodological considerations. The present study shares
he methodological challenges of other similar research and
vercomes some although not all of the challenges. Like
ther studies on this topic, ours was observational in nature.
hus, any observed associations could be attributable to
ther, unmeasured variables such as concomitant changes in
ther health-related behaviors (e.g., adoption of better
ating habits) or unequal distribution of co-interventions
mong the smoking categories. Such confounding would be
ess likely to occur in a randomized trial; however, such a
rial would be unethical, because it would require assigning
ome individuals to persistent smoking.
The study results are applicable to community patients
ges 65 years or less who underwent incident AMI—
hereby highly generalizable. Nevertheless, because patients
ho died during the index hospital stay were excluded, some
urvivor bias might exist. The follow-up period of 13 years
as long compared with follow-up periods in other studies:
he Wilson meta-analysis found a range of 2 to 10 years of
ollow-up, mostly 6 years (7).
An important advantage that this study has over other
tudies is that smoking status was ascertained repeatedly
ver time. Most of the studies (7,8) assess smoking at only
time point, and many of the authors note the consequent
roblem of misclassification of smoking status due to
ecidivism. The 5 repeated time points over a period of more
han 1 decade might provide a more accurate picture of true
moking habits in this study than would be possible from
valuation at a single point. Furthermore, inclusion of
moking status as well as other important confounders as
ime-dependent covariates in the regression models ensures
ppropriate analysis of these key variables. Thus, the meth-
dology used in this paper might overcome some although
ot all of the problems of recidivism and misclassification
aced by other authors.
Most previous studies were unable to differentiate be-
ween pre- and post-AMI quitters (8). Our methodology
llowed us to differentiate between these groups and so
solate the benefit of quitting after AMI. Thus, we provide
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his important juncture.
An additional limitation of this study is that, like most
imilar studies, it relied on self-report of smoking status. In
recent meta-analysis of cohort studies (7), only 1 of 12
tudies used biochemical validation of smoking status. That
eview noted that self-report of smoking status among
ost-AMI patients might be misrepresented by as many as
6% of the patients. Such misclassification might bias the
esults in an unknown direction.
The present study suggests that quitting smoking before
MI is associated with reduced mortality risk of 50%, whereas
uitting after AMI is associated with reduced mortality risk of
7%, compared with persistent smoking. As noted previously
8), these reductions seem at least as great as other secondary
reventive therapies, such as lowering cholesterol levels (a 29%
eduction) (28), aspirin (15%) (29), and beta-blockers (23%)
30). Furthermore, the survival benefit associated with smok-
ng cessation seen in this study was similar to that of under-
oing PTCA and greater than those of being normotensive or
ondiabetic.
onclusions
ontinuing to smoke after an AMI reduces life expectancy.
mokers who have had a heart attack should be provided
ith appropriate interventions to help them quit.
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